All In Biotech

NDA 020402 · Haleon US Holdings

Advil Liqui-Gels

Ibuprofen · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Apr 20, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

910

162 Phase 3, 61 recruiting

FAERS reports

246,695

163,952 serious, 17,657 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2026.

Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 16, 2000 Supplement 5 · Efficacy LabelReviewLetter
  • Apr 20, 1995 Original approval · Type 3 - New Dosage Form
2 products under this application
  • ADVIL LIQUI-GELS · IBUPROFEN EQ 200MG FREE ACID AND POTASSIUM SALT · CAPSULE, ORAL · Over-the-counter
  • ADVIL MIGRAINE LIQUI-GELS · IBUPROFEN EQ 200MG FREE ACID AND POTASSIUM SALT · CAPSULE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen" as an intervention, any sponsor and status, largest first.

All 910 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective23,101
  • pain17,688
  • fatigue17,381
  • nausea16,502
  • headache14,854
  • arthralgia12,682
  • dyspnoea12,107
  • diarrhoea11,637
  • vomiting11,557
  • rash10,407
  • off label use10,140
  • dizziness10,099

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,062
20052,689
20062,775
20072,597
20082,396
20093,422
20105,688
20117,295
20128,510
20139,667
20149,344
201513,337
201617,112
201714,706
201818,283
201919,101
202017,646
202118,963
202216,767
202315,536
202414,398
202514,424
20269,967

Recalls

1 FDA enforcement reports for this application.

  • Mar 16, 2020 · Class II · Terminated

    Labeling: Lacks Warning or Rx Legend- Certain lots does not include required safety warning information in the Drug Facts Panel.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,680 on PubMed

Sponsor: Haleon US Holdings · Also marketed as Advil Migraine Liqui-Gels

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.